TPG Biotech® supports physicians, scientists and entrepreneurs who are building innovation-based businesses in the life sciences. TPG Biotech®'s team of experienced investors, physicians, scientists, operators, and technical experts help build these companies. We invest for the long term, and are heavily involved in, and committed to, the growth and success of our portfolios.

TPG Biotech® invests across life science sectors, geographies, company stages, and asset classes. Our relationship with the broader TPG family of funds expands our global reach and investment size, and provides deep understanding of industrial markets. Our team believes that discoveries in the laboratory will generate novel therapeutics, diagnostics, devices and services, and may also be the basis of transforming the way we think about bioprocesses for fuels, foods, or specialty chemicals.

Since 2002, we have invested over half a billion dollars in over forty compelling lifescience businesses, spanning drug discovery, personalized diagnostic solutions, pharmaceutical services, medical devices, and industrial biotechnology. Through our relationship with the broader family of TPG funds, we can invest in all sizes of company and across an expanded geography. Such multi-fund investments include a take-private of a specialty pharma (Aptalis Pharma, previously Axcan Pharma), an investment in a leading clinical research organization (Quintiles), an investment in clinical chemistry outsourcing in China (ShangPharma), and an investment in the primary source for global healthcare market intelligence (IMS Health).